305 related articles for article (PubMed ID: 20214407)
1. Evaluation of in vivo P-glycoprotein phenotyping probes: a need for validation.
Ma JD; Tsunoda SM; Bertino JS; Trivedi M; Beale KK; Nafziger AN
Clin Pharmacokinet; 2010 Apr; 49(4):223-37. PubMed ID: 20214407
[TBL] [Abstract][Full Text] [Related]
2. Drug-Drug Interactions of P-gp Substrates Unrelated to CYP Metabolism.
Akamine Y; Yasui-Furukori N; Uno T
Curr Drug Metab; 2019; 20(2):124-129. PubMed ID: 30280663
[TBL] [Abstract][Full Text] [Related]
3. Investigation on modulation of human P-gp by multiple doses of Radix Astragali extract granules using fexofenadine as a phenotyping probe.
Zhou Q; Ye Z; Ruan Z; Zeng S
J Ethnopharmacol; 2013 Apr; 146(3):744-9. PubMed ID: 23422332
[TBL] [Abstract][Full Text] [Related]
4. A simplified protocol employing elacridar in rodents: a screening model in drug discovery to assess P-gp mediated efflux at the blood brain barrier.
Kallem R; Kulkarni CP; Patel D; Thakur M; Sinz M; Singh SP; Mahammad SS; Mandlekar S
Drug Metab Lett; 2012 Jun; 6(2):134-44. PubMed ID: 23061481
[TBL] [Abstract][Full Text] [Related]
5. In vivo probes of drug transport: commonly used probe drugs to assess function of intestinal P-glycoprotein (ABCB1) in humans.
Oswald S; Terhaag B; Siegmund W
Handb Exp Pharmacol; 2011; (201):403-47. PubMed ID: 21103977
[TBL] [Abstract][Full Text] [Related]
6. Suitability of digoxin as a P-glycoprotein probe: implications of other transporters on sensitivity and specificity.
Nader AM; Foster DR
J Clin Pharmacol; 2014 Jan; 54(1):3-13. PubMed ID: 24166743
[TBL] [Abstract][Full Text] [Related]
7. Modest effect of impaired P-glycoprotein on the plasma concentrations of fexofenadine, quinidine, and loperamide following oral administration in collies.
Kitamura Y; Koto H; Matsuura S; Kawabata T; Tsuchiya H; Kusuhara H; Tsujimoto H; Sugiyama Y
Drug Metab Dispos; 2008 May; 36(5):807-10. PubMed ID: 18299336
[TBL] [Abstract][Full Text] [Related]
8. Estimation of P-glycoprotein-mediated efflux in the oral absorption of P-gp substrate drugs from simultaneous analysis of drug dissolution and permeation.
Kataoka M; Yokoyama T; Masaoka Y; Sakuma S; Yamashita S
Eur J Pharm Sci; 2011 Nov; 44(4):544-51. PubMed ID: 21963456
[TBL] [Abstract][Full Text] [Related]
9. Circadian variations in exsorptive transport: in situ intestinal perfusion data and in vivo relevance.
Okyar A; Dressler C; Hanafy A; Baktir G; Lemmer B; Spahn-Langguth H
Chronobiol Int; 2012 May; 29(4):443-53. PubMed ID: 22489638
[TBL] [Abstract][Full Text] [Related]
10. 20(S)-ginsenoside Rh2 noncompetitively inhibits P-glycoprotein in vitro and in vivo: a case for herb-drug interactions.
Zhang J; Zhou F; Wu X; Gu Y; Ai H; Zheng Y; Li Y; Zhang X; Hao G; Sun J; Peng Y; Wang G
Drug Metab Dispos; 2010 Dec; 38(12):2179-87. PubMed ID: 20837659
[TBL] [Abstract][Full Text] [Related]
11. Kinetic identification of membrane transporters that assist P-glycoprotein-mediated transport of digoxin and loperamide through a confluent monolayer of MDCKII-hMDR1 cells.
Acharya P; O'Connor MP; Polli JW; Ayrton A; Ellens H; Bentz J
Drug Metab Dispos; 2008 Feb; 36(2):452-60. PubMed ID: 17967933
[TBL] [Abstract][Full Text] [Related]
12. Development, validation and utility of an in vitro technique for assessment of potential clinical drug-drug interactions involving P-glycoprotein.
Keogh JP; Kunta JR
Eur J Pharm Sci; 2006 Apr; 27(5):543-54. PubMed ID: 16406207
[TBL] [Abstract][Full Text] [Related]
13. Increased absorption of digoxin from the human jejunum due to inhibition of intestinal transporter-mediated efflux.
Igel S; Drescher S; Mürdter T; Hofmann U; Heinkele G; Tegude H; Glaeser H; Brenner SS; Somogyi AA; Omari T; Schäfer C; Eichelbaum M; Fromm MF
Clin Pharmacokinet; 2007; 46(9):777-85. PubMed ID: 17713975
[TBL] [Abstract][Full Text] [Related]
14. OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine.
Cvetkovic M; Leake B; Fromm MF; Wilkinson GR; Kim RB
Drug Metab Dispos; 1999 Aug; 27(8):866-71. PubMed ID: 10421612
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of first-pass cytochrome P4503A (CYP3A) and P-glycoprotein activities using alfentanil and fexofenadine in combination.
Kharasch ED; Walker A; Hoffer C; Sheffels P
J Clin Pharmacol; 2005 Jan; 45(1):79-88. PubMed ID: 15601808
[TBL] [Abstract][Full Text] [Related]
16. Capsaicin pretreatment enhanced the bioavailability of fexofenadine in rats by P-glycoprotein modulation: in vitro, in situ and in vivo evaluation.
Bedada SK; Appani R; Boga PK
Drug Dev Ind Pharm; 2017 Jun; 43(6):932-938. PubMed ID: 28102715
[TBL] [Abstract][Full Text] [Related]
17. If the KI is defined by the free energy of binding to P-glycoprotein, which kinetic parameters define the IC50 for the Madin-Darby canine kidney II cell line overexpressing human multidrug resistance 1 confluent cell monolayer?
Lumen AA; Acharya P; Polli JW; Ayrton A; Ellens H; Bentz J
Drug Metab Dispos; 2010 Feb; 38(2):260-9. PubMed ID: 19889884
[TBL] [Abstract][Full Text] [Related]
18. In vitro predictability of drug-drug interaction likelihood of P-glycoprotein-mediated efflux of dabigatran etexilate based on [I]2/IC50 threshold.
Kishimoto W; Ishiguro N; Ludwig-Schwellinger E; Ebner T; Schaefer O
Drug Metab Dispos; 2014 Feb; 42(2):257-63. PubMed ID: 24212378
[TBL] [Abstract][Full Text] [Related]
19. Recommended Daily Dose of Sesame Lignans Has No Influence on Oral Absorption of P-Glycoprotein Substrates in Rats.
Tomono T; Otsuka K; Yano K; Kanagawa M; Arakawa H; Ogihara T
Biol Pharm Bull; 2015; 38(12):1960-3. PubMed ID: 26632187
[TBL] [Abstract][Full Text] [Related]
20. A P-gp vesicular transport inhibition assay - optimization and validation for drug-drug interaction testing.
Herédi-Szabó K; Palm JE; Andersson TB; Pál Á; Méhn D; Fekete Z; Beéry E; Jakab KT; Jani M; Krajcsi P
Eur J Pharm Sci; 2013 Jul; 49(4):773-81. PubMed ID: 23684934
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
